Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study

References

• Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev. 2010;9:A293–8.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Flossmann 0, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA. Out-comes from studies of antineutrophil cytoplasm antibody asso-ciated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67: 1004–10.
   Google Scholar
• Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97–111.
   PubMed Web of Science ®Google Scholar
• Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to metho-trexate treatment. Ann Rheum Dis. 2007;66:189–94.
   PubMed Web of Science ®Google Scholar
• Mittendorf T, Dietz B, Sterz R, Kupper H, Cifaldi MA, von der Schulenburg JM. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol. 2007;34:2343–50.
   Google Scholar
• Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20–30.
   Google Scholar
• Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35:206–15.
   PubMed Web of Science ®Google Scholar
• Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsive-ness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67:260–5.
   Google Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61:4–12.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Flossmann 0, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associ-ated vasculitis. Ann Rheum Dis. 2007;66: 605–17.
   Google Scholar
• Merkel PA, Herlyn K, Mahr AD, Neogi T, Seo P, Walsh M, Boers M, Luqmani R. Progress towards a core set of outcome measures in small-vessel vasculitis: report from OMERACT 9. J Rheumatol. 2009;36:2362–8.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, Kurihara Y, Kurokawa MS, Makino H, Nagafuchi H, Nakabayashi K, Nishimoto N, Suka M, Tomino Y, Yamada H, Yamagata K, Yoshida M, Yumura W. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2011 (in press).
   Google Scholar
• Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.
   PubMedGoogle Scholar
• Flossmann 0, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.
   PubMed Web of Science ®Google Scholar
• Fukuhara S, Suzukamo Y. Manual of SF-36 v2, Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation Research; 2004. (in Japanese).
   Google Scholar
• Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis. 2009;68:1800–4.
   PubMed Web of Science ®Google Scholar
• Carpenter DM, Thorpe CT, Lewis M, Devellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum. 2009;61:259–65.
   Google Scholar
• Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49: 826–37.
   PubMed Web of Science ®Google Scholar
• Newall C, Schinke S, Savage CO, Hill S, Harper L. Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology. 2005;44:623–8.
   Google Scholar
• Koutantji M, Pearce S, Harrold E. Psychological aspects of vasculitis. Rheumatology. 2000;39:1173–9.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C. A randomized trial of main-tenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.
   Google Scholar
• De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–9.
   Google Scholar